NASDAQ:BRTX

Biorestorative Therapies Stock News

Healthcare > Biotechnology

Buy BRTX

*Your capital is at risk

$0.339

-0.0150 (-4.23%)

At Close: Jun 03, 2026

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

08:30am, Tuesday, 24'th Feb 2026

MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a late stage clinical regenerative medicine in

BioRestorative Announces Closing of $5.0 Million Public Offering

08:30pm, Friday, 13'th Feb 2026

MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine inno

BioRestorative Announces Pricing of $5.0 Million Public Offering

10:30pm, Wednesday, 11'th Feb 2026

MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine inno

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

07:30am, Wednesday, 11'th Feb 2026

MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ), a late stage clinical regenerative medicine inn

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

08:00am, Tuesday, 10'th Feb 2026

Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

07:00am, Monday, 17'th Nov 2025

MELVILLE, N. Y. , Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a regenerative medicine innovator focused on stem cell-ba

Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates

07:26pm, Wednesday, 12'th Nov 2025

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.13 per share a year ago.

BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript

06:51pm, Wednesday, 12'th Nov 2025

BioRestorative Therapies, Inc. ( BRTX ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Stephen Kilmer - Investor Relations Officer Lance Alstodt - Chairman of the Board, Pres

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

04:30pm, Wednesday, 05'th Nov 2025

MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on s

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

07:30am, Monday, 27'th Oct 2025

MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on s

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

09:35am, Wednesday, 22'nd Oct 2025

MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on s

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by